



# The global leader in developing LAG-3 therapeutics

Australia Biotech Invest & Partnering  
30th October 2018

*(ASX: IMM, NASDAQ: IMMP)*

# Notice: Forward Looking Statements

*The purpose of the presentation is to provide an update of the business of Immunetep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Immunetep and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.*

*The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Immunetep's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Immunetep's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.*

*Additionally, the INSIGHT investigator sponsored clinical trial described in this presentation is controlled by the lead investigator and therefore Immunetep has no control over this clinical trial. This presentation should not be relied on as a recommendation or forecast by Immunetep. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

# Company Snapshot


- Globally active biotechnology company with operations in Australia, Europe and U.S.
- Four LAG-3 related product candidates in development in immuno-oncology and autoimmune disease
- Committed partnerships with five of the world's largest pharmaceutical companies - Merck (MSD), Pfizer/ Merck KGaA, Novartis and GSK, along with Eddingpharm in China

## Capital Structure

<b>Ticker symbols</b>	IMM (Australian Securities Exchange) IMMP (NASDAQ)
<b>Securities on issue<sup>(1)</sup></b> (as at 23 October 2018)	3.08 billion ordinary shares 8.83 million American Depository Shares (ADSs)
<b>Cash &amp; Term Deposits</b> (as at 30 September 2018)	A\$21.3 million (~US\$15.4 million)
<b>Market Cap</b> (as at 23 October 2018)	A\$138.6 million (~US\$97.9 million)
<b>Avg. Vol. (3 months)</b> (as at 23 October 2018)	5.0 million ordinary shares on ASX 142 k ADRs <sup>(1)</sup> on NASDAQ

<sup>(1)</sup> Market capitalisation based on ASX ordinary share price. For a detailed summary of all securities on issue refer to latest Appendix 3B released on ASX. Each ADR represents 100 ordinary shares

## Shareholders




■ Australian Securities Exchange ■ Nasdaq

# LAG-3 Overview & Product Candidates

# LAG-3 as a Therapeutic Target

LAG-3 is widely expressed on tumour infiltrating lymphocytes (TILs) and cytotoxic T cells →  
**Prime target for an immune checkpoint blocker**




→ **Positive regulation** of antigen presenting cells (APC) → increase in antigen presentation to cytotoxic CD8<sup>+</sup> T cells

→ **Negative regulation** of LAG-3<sup>+</sup> T Cells

*Notes:*  
\* APC: antigen presenting cell

# Targeting LAG-3 May Lead to Multiple Therapeutics in Numerous Indications



# Oncology and Autoimmune Pipeline\*

Program	Preclinical	Phase I	Phase II	Late Stage	Commercial Rights/Partners
Eftilagimod Alpha (LAG-3lg or IMP321), APC activating fusion protein	AIPAC (Chemo-IO Combo)			2019	Global Rights Chinese Rights
	TACTI-002 <sup>(1)</sup> (IO-IO Combo)		2019/2020	MERCK INVENTING FOR LIFE	
	INSIGHT-004 <sup>(2),(3),(5)</sup> (IO-IO Combo)	2019/2020	Pfizer	Merck KGaA, Darmstadt, Germany	
	TACTI-mel (IO-IO Combo)	2018/2019			
	INSIGHT <sup>(2)</sup> (In situ Immunization)	2018/2019			
IMP731 (Depleting AB)	Autoimmune Diseases <sup>(4)</sup>				Global Rights
IMP701 (Antagonist AB)	IO-IO Combo: solid tumours IO-IO Combo: solid tumours + blood cancer Chemo-IO combo: metastatic breast cancer IO-IO Combo: melanoma <sup>(5)</sup>				Global Rights  NOVARTIS
IMP761 (Agonist AB)	Autoimmune Diseases				Global Rights

Notes

\* Actual timing of data readouts may differ from expected timing shown above.


(1) In combination with KEYTRUDA® (pembrolizumab) in non-small cell lung carcinoma ("NSCLC") or head and neck carcinoma ("HNSCC"); clinical trial is currently planned and not active.

(2) INSIGHT Investigator Initiated Trial ("IIT") is controlled by lead investigator and therefore ImmuteP has no control over this clinical trial.

(3) In combination with BAVENCIO® (avelumab).

(4) Reflects completed Phase I study in psoriasis and anticipated Phase II trial in ulcerative colitis.



(5) Clinical trial is currently planned and not active.



# Efti (IMP321) in Melanoma

## TACTI-mel (IO combination) – Single Case at 1 mg efti

### Efficacy: Metastatic Melanoma






**All lesions disappeared → CR (confirmed)  
patient without further treatment and disease free**



# LAG-3 Therapeutic Landscape Overview

*ImmuteP is the leader in developing LAG-3 modulating therapeutics*



Indicates one product; size indicates stage of development, green = product either developed by ImmuteP or under license from ImmuteP

Indicates No. of patients on trials

## Potential News Flow and Milestones

### Clinical

- TACTI-mel data from fourth patient cohort (30 mg dose at cycle 1): H2 2018
- TACTI-002 to commence, Phase II trial in collaboration with MSD: H2 2018
- TACTI-002 first data in 2019
- IMP761 preclinical data: 2018/ 2019
- INSIGHT single cases from study: throughout 2019
- AIPAC first progression free survival data (metastatic breast cancer trial): 2019

### Other

- Potential milestone payments from clinical partners as trials progress
- Continued expansion of patent portfolio
- Continued regulatory interaction
- Ongoing business development activities

**Thank you!**